Journal Clinical Oncology - The transplantation program with RVD induction and consolidation followed by lenalidomide maintenance produced high-quality responses and showed favorable tolerability in patients with newly diagnosed MM.
Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome
Purpose The three-drug combination of lenalidomide, bortezomib, and dexamethasone (RVD) has shown significant efficacy in multiple myeloma (MM). The Intergroupe Francophone du Myélome (IFM) decided to evaluate RVD induction and consolidation therapies in a sequential intensive strategy for previously untreated transplantation-eligible patients with MM.
Patients and Methods In this phase II study, 31 symptomatic patients age
She is a freakin genius. Look the stocks she talked about are going down? Its results that count. What else are you looking for?--LOL.
Maybe CELG can design a drug that prevents people from saying stupid things while public speaking. I'm sure Yellen could use it.
I should call Janet Yellen and see what her numbers are for the new chron's disease drug. Maybe my numbers are too aggressive. Personally anyone who would sell anything on her remarks is too stupid to be in the market to begin with.
Nice! I wonder if she gets double pay? One salary as fed chair, and another as a stock analyst?
She did not do CELG any favors...wench!
Employees tend to follow the management style of the "boss". Just as Obama decided he knew which solar energy companies would succeed (Sylondra), Yellon thinks she knows which segments of the market, which is a #$%$ shoot anyway, will prosper in the future. Prices in the market are determined by what sellers and buyers agree on, not by an appointed Fed official.
Sentiment: Strong Buy
Retail doesn't carry the volume, but on the whole they (we?) can effectively play the part of "patsy". Somebody has to get left holding he proverbial bag. The Goldman Sachs name still carries weight with retail, even if the following isn't as large as it used to be.
1. If Nuvilex has completed the necessary preliminary steps to commence a Phase 2b clinical trial of its pancreatic cancer treatment that it expects to begin in Q1 2015, then why hasn't the FDA Centers for
Biological Evaluation & Research at 800-835-4709 ever heard of NVLX or its subsidiary Austrianova?
2. If NVLX was virtually debt free, then explain an accumulated deficit of (52,229,316) according to the last NVLX 10-Q dated 03/17/14???
3. If Nuvilex has secured a traditional investment banking relationship with Chardan Capital Markets, then why no funding from Chardan itself? It's just an agreement for Chardan to peddle NVLX stock for a fee according to the 05/29/14 8-K!!!
4. If Nuvilex has established credibility with accredited and institutional investors, why not mention any names? No proof of this whatsoever!!!
MORTGAGE YOUR HOUSE TO SHORT THIE NVLX CRIMINAL ENTERPRISE IF YOU WANNA GET RICH BEFORE THE SEC SHUTS IT DOWN FOR GOOD!!!!!!!!!!!!!
Sentiment: Strong Sell
Sentiment: Strong Sell
I think the scarier issue from this day comes from Goldman's change over to BULLISH recommendation on equities - which actually means that a top may be near for US markets. The thieves at GS will be selling, you can be sure.
JMP- Read-through to Celgene from JNJ 2Q14 Earnings - "We continue to view CELG as our top large-cap pick and reaffirm our estimates and Market Outperform rating"
JMP today - Read-through to Celgene from JNJ 2Q14 Earnings
MARKET OUTPERFORM | Price: $88.11 | Target Price: $102.00
Johnson and Johnson (JNJ, NC) reported 2Q14 earnings today, disclosing ex-U.S. Velcade sales of $403MM; maintaining Market Outperform rating on Celgene and $102 YE14 price target, derived through DCF and P/E multiple valuation methodologies. Ex-U.S. Velcade sales were $403MM for the quarter - a 1.2% sequential decline from 1Q14 sales ($408MM) and 6.4% gain year over year (from $379MM). For Celgene, we reaffirm our projected 2Q14 ex-U.S. ($516.5MM) and worldwide ($1.2bn) Revlimid estimates, and non-GAAP EPS estimate of $0.88. CELG reports its 2Q14 earnings results on July 24, before market open.
Sequentially flat quarter for Velcade reflects product maturation in the RRMM setting, with limited read-through to overall market growth. As noted above, Velcade growth year over year was modest at 6.4% (6.2% constant currency), and likely primarily a result of price rather than volume. In our view, this trend reflects a leveling in penetration typical of a mature product, and as an IV product, one particularly susceptible to oral agents (Revlimid, Pomalyst). While Q2 results may imply Velcade losing ground to the Celgene myeloma franchise near term, we maintain the view that the primary driver for Revlimid growth longer term will be uptake in the newly diagnosed maintenance setting.
We remain bullish on Celgene and forecast total revenues to rise to $17bn+ by 2020. We expect Celgene’s four blockbuster drugs (Revlimid, Abraxane, Otezla, and Pomalyst) to drive revenues in excess of $13.4bn by 2017, and $17bn by 2020, while investments in collaborators like Acceleron, Epizyme, Oncomed, Agios and others ensure growth from 2017 and beyond. We continue to view CELG as our t
as like 4 months ago, any sell off in celg is a good buying opportunity. celg isn't a small biotech and doesn't have a stretched valuation. it trades at 27x this years earnings and has a 25% growth rate. that is by no means stretched.